

# Contents

## Volume I

<b>Preface</b> .....	iii
<b>1. Executive Summary</b> .....	1
<b>2. Introduction</b> .....	11
<b>2.1</b> Purpose of this Report .....	12
<b>2.2</b> Target Audiences of this Report .....	15
<b>2.3</b> Organization of this Report .....	15
<b>2.3.1</b> Management of Persons Contaminated with Radionuclides: Handbook .....	16
<b>2.3.2</b> Part A: Quick Reference Information .....	19
<b>2.3.3</b> Part B: Onsite and Prehospital Actions .....	19
<b>2.3.4</b> Part C: Patient Management at Hospital .....	20
<b>2.3.5</b> Part D: Patient Management Post-Hospital .....	20
<b>2.3.6</b> Management of Persons Contaminated with Radionuclides: Scientific and Technical Bases .....	21
<b>Part A: Quick Reference Information</b>	
<b>3. Compendium of Radiation Facts and Guidance</b> .....	25
<b>3.1</b> Introduction .....	25
<b>3.1.1</b> Organizations Offering Radiological Incident Assistance .....	25
<b>3.1.2</b> Terminology .....	26
<b>3.2</b> Basic Radiological Facts .....	30
<b>3.2.1</b> Radiation Types and Recommended Personnel Protection .....	30
<b>3.2.2</b> Identifying Radiation Types Using a Pancake or Other Thin End-Window Geiger-Mueller Probe Survey Meter .....	31
<b>3.2.3</b> Radiation Energy and Radioactive Decay Facts .....	32
<b>3.3</b> Incident Response (Section 18) .....	33
<b>3.3.1</b> Incidents .....	33
<b>3.3.1.1</b> Small Scale .....	33
<b>3.3.1.2</b> Large Scale .....	34
<b>3.3.2</b> Roles and Responsibilities (Section 18) .....	34
<b>3.4</b> Guidance for Professionals at Incident Site .....	35

<b>3.4.1</b>	Radiation Readings and Their Significance (dose-rate meters) . . . . .	36
<b>3.4.2</b>	Surface Radiation Readings and Their Significance (contamination survey meters) . . . . .	37
<b>3.5</b>	Management of Potentially-Injured and Contaminated Persons . . . . .	38
<b>3.5.1</b>	Priorities for Aiding Contaminated Individuals . . . . .	38
<b>3.5.2</b>	Stages in Management of Exposed Persons . . . . .	38
<b>3.6</b>	Radiation Exposures from External Sources . . . . .	42
<b>3.6.1</b>	Health Effects from External Radiation . . . . .	42
<b>3.6.2</b>	Neutron-Radiation Dose from Criticality Accident (based on <sup>24</sup> Na activation in body) . . . . .	42
<b>3.6.3</b>	Exposures from Sealed Radioactive Sources . . . . .	45
<b>3.7</b>	Air Kerma and Skin Doses for Point Sources . . . . .	46
<b>3.7.1</b>	Intervention Levels for Skin Contamination . . . . .	46
<b>3.7.2</b>	Guidance for Decontaminating Skin . . . . .	49
<b>3.8</b>	Radiation Exposures from Internal Depositions of Radionuclides . . . . .	49
<b>3.8.1</b>	Health Effects from Internal Radionuclide Contamination . . . . .	49
<b>3.8.1.1</b>	Deterministic Effects (harmful tissue reactions) . . . . .	49
<b>3.8.1.2</b>	Stochastic Effects . . . . .	52
<b>3.8.1.2.1</b>	Cancer . . . . .	52
<b>3.8.1.2.2</b>	Hereditary effects (Section 16.7.2.2). . . . .	52
<b>3.8.1.3</b>	Developmental Effects (Section 16.7.3) . . . . .	52
<b>3.8.2</b>	Inhalation Intakes . . . . .	54
<b>3.8.2.1</b>	Air Samples . . . . .	54
<b>3.8.2.2</b>	Nasal Swabs . . . . .	54
<b>3.8.2.3</b>	Doses Received from Inhaled Radionuclides . . . . .	56
<b>3.8.3</b>	Intakes Through Skin and Ingestion . . . . .	56
<b>3.9</b>	Medical Management of Internal Radionuclide Depositions . . . . .	56
<b>3.9.1</b>	Clinical Decision Guides . . . . .	56
<b>3.9.2</b>	Decorporation Therapy . . . . .	63
<b>3.10</b>	Radiation Dose Limitation . . . . .	63
<b>4.</b>	<b>Radiation-Safety Guidance for First Responders . . . . .</b>	<b>72</b>
<b>4.1</b>	Introduction . . . . .	72
<b>4.2</b>	General Instructions for First Responders . . . . .	73
<b>4.3</b>	Guidance for First Responders . . . . .	74
<b>4.3.1</b>	First on the Scene . . . . .	75

4.3.2	Immediate Goals for Protection of Exposed Individuals . . . . .	75
4.3.3	Control Areas . . . . .	76
4.3.4	Protection of First Responders . . . . .	78
<b>5.</b>	<b>Performing Surveys and Controlling Personnel and Area Contamination . . . . .</b>	<b>80</b>
5.1	Contamination Surveys . . . . .	80
5.1.1	How to Perform Surveys of Individuals, Clothing, Samples and Surfaces . . . . .	81
5.1.2	How to Perform a Beta/Gamma-Radiation Area Survey . . . . .	82
5.1.3	How to Perform an Alpha-Radiation Survey of Contaminated Areas, Individuals and Samples . . . . .	82
5.2	Personal Protection Equipment . . . . .	83
5.2.1	Examples of Personal Protection Equipment . . . . .	83
5.2.2	Personal Protection Equipment Inspection . . . . .	83
5.2.3	Dressing in Personal Protection Equipment . . . . .	86
5.2.4	Removing Personal Protection Equipment . . . . .	86
5.2.5	Actions to be Taken after Personal Protection Equipment is Removed . . . . .	88
5.3	Contamination Control . . . . .	88
5.3.1	Contamination Control Practices . . . . .	88
5.3.2	Contamination Control of Exposed People . . . . .	88
5.3.3	Contamination Control Among Medical and Emergency- Response Personnel . . . . .	89
5.3.4	Radiologically-Controlled Areas (further defined in Sections 4.3.3 and 18) . . . . .	89
5.3.4.1	General Guidelines for Operation of a Controlled Contamination Area . . . . .	90
5.3.4.2	Leaving a Controlled Area . . . . .	91
5.3.4.3	Transportation of Injured and Contaminated Individuals. . . . .	91
5.3.5	Decontamination of Equipment . . . . .	92
	<b>Part B: Onsite and Prehospital Actions</b>	
<b>6.</b>	<b>Stage 1: Medical Assessment (onsite triage area) . . . . .</b>	<b>93</b>
6.1	Initial Actions of Medical and Radiation Safety Personnel . . . . .	94
6.2	Potential Life-Threatening Problems . . . . .	94
6.3	Identification of Individuals Exposed to Radiation and/or Radionuclides . . . . .	96
6.4	Assessment of External Irradiation . . . . .	96
6.5	Contamination Screening of Individuals . . . . .	101
6.5.1	External Contamination . . . . .	101

<b>6.5.2</b>	Internal Contamination . . . . .	101
<b>6.5.2.1</b>	Inhalation Intakes . . . . .	102
<b>6.5.2.2</b>	Intakes Through Skin and Ingestion . . . . .	103
<b>6.5.2.3</b>	Collection of Excreta . . . . .	103
<b>6.6</b>	Onsite Treatment for Internal Contamination . . . . .	104
<b>6.7</b>	Priorities in Processing Exposed Persons . . . . .	104
<b>6.8</b>	Documenting a Radionuclide Contamination Incident . . . . .	104
<b>7.</b>	<b>Stage 2: External Contamination Assessment</b>	
	<b>(onsite triage area)</b> . . . . .	107
<b>7.1</b>	External Contamination Assessment Procedures . . . . .	107
<b>7.2</b>	Dose Assessment . . . . .	109
<b>7.3</b>	Screening Guidance . . . . .	111
<b>7.4</b>	Treatment Guidance . . . . .	111
<b>8.</b>	<b>Stage 3: External Decontamination</b>	
	<b>(onsite decontamination area)</b> . . . . .	113
<b>8.1</b>	Decontamination of Persons . . . . .	113
<b>8.1.1</b>	Decontamination Objectives . . . . .	114
<b>8.1.2</b>	Decontamination Procedures . . . . .	115
<b>8.2</b>	Guidance for Those Performing Decontamination	
	Procedures . . . . .	117
<b>8.3</b>	Decontamination Facilities . . . . .	118
<b>8.4</b>	Saving Contaminated Materials . . . . .	120
<b>8.5</b>	Management of Individuals After Contamination	
	Assessment and Decontamination of Skin and	
	Wounds . . . . .	120
<b>8.6</b>	Documentation . . . . .	121
	<b>Part C: Patient Management at Hospital</b>	
<b>9.</b>	<b>Stage 4: Patient Evaluation and Emergency Care</b>	
	<b>(hospital)</b> . . . . .	123
<b>9.1</b>	General Issues in Initial Patient Evaluation . . . . .	124
<b>9.1.1</b>	Medical Evaluation of Persons with Internal	
	Contamination . . . . .	124
<b>9.1.2</b>	Psychological and Behavioral Consequence	
	Management After Radiation Incidents . . . . .	125
<b>9.2</b>	General Instructions for Emergency Department	
	Medical Staff . . . . .	127
<b>9.3</b>	Emergency Medical Management . . . . .	128
<b>9.3.1</b>	Caring for Contaminated Individuals with	
	Life-Threatening Injuries . . . . .	128
<b>9.3.2</b>	Caring for Lightly Injured and Uninjured	
	Contaminated Exposed Persons . . . . .	128

<b>9.3.3</b>	Caring for Persons Suffering from Radiation Injury .....	129
<b>9.3.4</b>	Caring for Persons Suffering from Radiation Burns .....	131
<b>9.4</b>	Initial Treatment Decisions .....	132
<b>9.4.1</b>	Radionuclides in a Wound .....	132
<b>9.4.2</b>	Radionuclide Inhalation .....	133
<b>9.4.3</b>	Radionuclide Ingestion .....	134
<b>9.4.3.1</b>	Gastric Lavage .....	134
<b>9.4.3.2</b>	Emetics .....	135
<b>9.4.3.3</b>	Purgatives .....	135
<b>9.4.4</b>	Clinical Decision Guides .....	136
<b>9.4.5</b>	Specific Drug Decorporation Therapy .....	136
<b>9.4.6</b>	Algorithm for Medical Management of Internal Depositions .....	136
<b>9.5</b>	Medical Information Checklist .....	136
<b>10.</b>	<b>Stage 5: Internal Contamination Assessment (hospital)</b> .....	138
<b>10.1</b>	Preliminary Assessment Activities .....	138
<b>10.2</b>	Information About the Contaminating Incident .....	140
<b>10.2.1</b>	Location of the Individual and Time of Exposure .....	140
<b>10.2.2</b>	Establishing the Route of Exposure .....	141
<b>10.2.3</b>	Radionuclide Identification and Physical and Chemical Form .....	142
<b>10.3</b>	Bioassay .....	143
<b>10.3.1</b>	Indirect ( <i>in vitro</i> ) Bioassay Monitoring .....	144
<b>10.3.1.1</b>	Nasal Swabs .....	144
<b>10.3.1.2</b>	Urine Bioassay .....	146
<b>10.3.1.3</b>	Fecal Samples .....	150
<b>10.3.1.4</b>	Blood Samples .....	150
<b>10.3.1.5</b>	Tissue Specimens .....	151
<b>10.3.2</b>	Direct ( <i>in vivo</i> ) Monitoring .....	151
<b>10.3.2.1</b>	Whole-Body Counting .....	152
<b>10.3.2.2</b>	Chest (lung) Counting .....	152
<b>10.3.2.3</b>	Counting of Particular Organs or Tissues .....	152
<b>10.4</b>	Intake and Dose Assessment .....	153
<b>11.</b>	<b>Stage 6: Clinical Decision Guidance (hospital)</b> .....	158
<b>11.1</b>	Introduction .....	158
<b>11.2</b>	Clinical Decision Guides .....	158
<b>11.3</b>	Clinical Decision Guide Instrument Considerations .....	169
<b>11.4</b>	Extrapolation of Data for Spot Urine Sample to 24 h Values .....	169
<b>11.5</b>	Worked Examples with Bioassay Data .....	171

<b>12. Stage 7: Medical Management (hospital)</b>	176
<b>12.1</b> Introduction	177
<b>12.2</b> Decorporation Therapy for Internally-Deposited Radionuclides	179
<b>12.3</b> Decorporation Therapy by Drug	187
<b>12.3.1</b> Deferoxamine Treatment	187
<b>12.3.2</b> Dimercaprol Treatment	189
<b>12.3.3</b> DTPA Treatment	191
<b>12.3.4</b> Ethylenediaminetetraacetic Acid Treatment	198
<b>12.3.5</b> Penicillamine Treatment	199
<b>12.3.6</b> Prussian Blue Insoluble Treatment	201
<b>12.3.7</b> Succimer Treatment	209
<b>12.4</b> Medical Treatments Arranged by Radionuclide	210
<b>12.4.1</b> Medical Treatment for Barium and Calcium Radionuclides	210
<b>12.4.2</b> Medical Treatment for Cobalt Radionuclides	212
<b>12.4.3</b> Medical Treatment for Iodine Radionuclides	212
<b>12.4.4</b> Medical Treatment for Radioactive Phosphorus	221
<b>12.4.5</b> Medical Treatment for Radium and Strontium Radionuclides	221
<b>12.4.6</b> Medical Treatment for Tritium (radioactive hydrogen)	228
<b>12.4.7</b> Medical Treatment for Uranium Isotopes	228
<b>12.4.8</b> Medical Treatment for the Actinide Nuclides (Section 12.3.3)	233
<b>12.5</b> Lung Lavage	233
 <b>Part D: Patient Management Post-Hospital</b>	
<b>13. Stage 8: Follow-Up Medical Care</b>	237
<b>13.1</b> Introduction	237
<b>13.2</b> Late-Occurring Health Effects	238
<b>13.3</b> Preventive Medicine Approaches	239
<b>13.4</b> Psychosocial Issues	240
 <b>14. Stage 9: Contaminated Decedents (hospital and mortuary)</b>	
<b>14.1</b> Introduction	244
<b>14.2</b> Guidelines for the Medical Examiner	245
<b>14.2.1</b> Field Activities	245
<b>14.2.2</b> Autopsy	247
<b>14.3</b> Guidelines for Mortuary Personnel	251
<b>14.4</b> Final Disposition of the Decedent	252
<b>14.5</b> Religious and Cultural Considerations	253

<b>15. Contamination Control in Medical Facilities</b> . . . . .	255
15.1 Introduction . . . . .	255
15.2 Standard Precautions . . . . .	255
15.3 Contamination Control Actions in the Emergency Department for Highly-Contaminated Patients . . . . .	256
15.4 Working with Contaminated Patients . . . . .	257
15.5 Hospital Emergency Department Contamination Controls . . . . .	257
15.6 Contaminated Patients' Rooms . . . . .	259
15.7 Patient Decontamination (Section 8) . . . . .	259
15.8 Responsibilities of Radiation-Safety Personnel . . . . .	260
15.9 Hospital Decontamination Procedures for Protection of Personnel and Facilities . . . . .	260
<b>References</b> . . . . .	263
<b>Index</b> . . . . .	277

## Volume II

<b>Preface</b> . . . . .	iii
--------------------------	-----

<b>16. Overview of Radiobiology Concepts Pertinent to   Radionuclides</b> . . . . .	287
16.1 Introduction . . . . .	287
16.2 Radionuclides and Radiation . . . . .	288
16.3 General Characteristics of Radionuclide and Radiation Exposures . . . . .	293
16.4 Radionuclides as Internal Health Risks . . . . .	296
16.5 Routes of Entry into the Body . . . . .	297
16.5.1 Skin and Wound Contamination. . . . .	298
16.5.2 Inhalation of Radionuclides. . . . .	300
16.5.3 Ingestion of Radionuclides. . . . .	308
16.6 Internal Dosimetry Models . . . . .	310
16.7 Quantities Used in Radiation Protection . . . . .	312
16.7.1 Units of Activity in Current Use . . . . .	312
16.7.2 Dosimetric Quantities and Units in Current Use . . . . .	313
16.8 Health Effects from Radiation Exposures . . . . .	315
16.8.1 Deterministic Effects . . . . .	319
16.8.1.1 Thresholds and Unrecoverable Levels for Deterministic Effects. . . . .	319
16.8.1.2 Dependence of Threshold and $D_{50}$ Values on Dose Rate . . . . .	324

	<b>16.8.1.3</b>	Acute Radiation Syndrome . . . . .	324
	<b>16.8.1.4</b>	Relative Biological Effectiveness .	325
	<b>16.8.1.5</b>	Deterministic Effects of Concern Following Intakes of Radionuclides . . . . .	326
	<b>16.8.1.6</b>	Beta Burns . . . . .	327
	<b>16.8.1.7</b>	Hematopoietic (bone-marrow) Failure . . . . .	329
	<b>16.8.1.8</b>	Impaired Pulmonary Function . . .	330
	<b>16.8.1.9</b>	Gastrointestinal System Failure . .	338
	<b>16.8.1.10</b>	Thyroid . . . . .	339
	<b>16.8.1.11</b>	Summary of Deterministic Health Effects . . . . .	339
	<b>16.8.2</b>	Stochastic Effects . . . . .	341
	<b>16.8.2.1</b>	Cancer . . . . .	343
	<b>16.8.2.2</b>	Hereditary Effects . . . . .	356
	<b>16.8.3</b>	Developmental Effects . . . . .	358
	<b>16.8.4</b>	Hot Particles . . . . .	359
<b>16.9</b>		Summary . . . . .	360
	<b>16.9.1</b>	Use of Dose Quantities and Units . . . . .	360
	<b>16.9.2</b>	Deterministic and Stochastic Health Effects .	361

<b>17. Settings in Which Individuals May be Contaminated with Radionuclides . . . . .</b>	<b>363</b>
<b>17.1</b> Introduction . . . . .	<b>363</b>
<b>17.2</b> Types of Contamination Incidents . . . . .	<b>363</b>
<b>17.2.1</b> Small Scale . . . . .	<b>363</b>
<b>17.2.2</b> Large Scale . . . . .	<b>364</b>
<b>17.2.3</b> Accidental . . . . .	<b>365</b>
<b>17.2.4</b> Deliberate . . . . .	<b>366</b>
<b>17.3</b> Settings in Which Contamination Incidents May Occur . . . . .	<b>367</b>
<b>17.3.1</b> Malicious Use: Stolen or Improvised Nuclear Device . . . . .	<b>391</b>
<b>17.3.1.1</b> Examples of Contamination Incidents . . . . .	<b>392</b>
<b>17.3.1.2</b> Likely Radionuclides Involved . . .	<b>392</b>
<b>17.3.1.3</b> Radiological Considerations . . . . .	<b>392</b>
<b>17.3.1.4</b> Important Nonradiological Considerations . . . . .	<b>392</b>
<b>17.3.1.5</b> Examples and Descriptions of Sources and Devices . . . . .	<b>393</b>
<b>17.3.2</b> Malicious Use: Radiological Dispersal Device	<b>393</b>
<b>17.3.2.1</b> Examples of Contamination Incidents . . . . .	<b>394</b>



	<b>17.3.2.2</b>	Radiological Considerations . . . . .	394
	<b>17.3.2.3</b>	Important Nonradiological Considerations . . . . .	396
	<b>17.3.2.4</b>	Examples and Descriptions of Sources and Devices . . . . .	396
<b>17.3.3</b>		Malicious Use: Contamination of Food or Water Supply . . . . .	396
	<b>17.3.3.1</b>	Examples of Contamination Incidents . . . . .	397
	<b>17.3.3.2</b>	Likely Radionuclides Involved . . . . .	397
	<b>17.3.3.3</b>	Radiological Considerations . . . . .	397
	<b>17.3.3.4</b>	Important Nonradiological Considerations . . . . .	398
	<b>17.3.3.5</b>	Examples and Descriptions of Sources and Devices . . . . .	398
<b>17.3.4</b>		Malicious Use: Deliberate Contamination of Another Individual . . . . .	398
	<b>17.3.4.1</b>	Examples of Contamination Incidents . . . . .	399
	<b>17.3.4.2</b>	Likely Radionuclides Involved . . . . .	399
	<b>17.3.4.3</b>	Radiological Considerations . . . . .	399
	<b>17.3.4.4</b>	Important Nonradiological Considerations . . . . .	400
	<b>17.3.4.5</b>	Examples and Descriptions of Sources and Devices . . . . .	400
<b>17.3.5</b>		Nuclear Reactors . . . . .	400
	<b>17.3.5.1</b>	Examples of Contamination Incidents . . . . .	401
	<b>17.3.5.2</b>	Radiological Considerations . . . . .	401
	<b>17.3.5.3</b>	Important Nonradiological Considerations . . . . .	404
	<b>17.3.5.4</b>	Examples and Descriptions of Sources and Devices . . . . .	405
<b>17.3.6</b>		Industrial: Source Manufacture . . . . .	405
	<b>17.3.6.1</b>	Examples of Contamination Incidents . . . . .	406
	<b>17.3.6.2</b>	Likely Radionuclides Involved . . . . .	406
	<b>17.3.6.3</b>	Radiological Considerations . . . . .	406
	<b>17.3.6.4</b>	Important Nonradiological Considerations . . . . .	407
<b>17.3.7</b>		Industrial: Source Use . . . . .	407
	<b>17.3.7.1</b>	Examples of Contamination Incidents . . . . .	408
	<b>17.3.7.2</b>	Radiological Considerations . . . . .	408

	<b>17.3.7.3</b>	Important Nonradiological Considerations . . . . .	410
	<b>17.3.7.4</b>	Examples and Descriptions of Sources and Devices . . . . .	410
<b>17.3.8</b>		Radioactive-Material Transportation . . . . .	410
	<b>17.3.8.1</b>	Examples of Contamination Incidents . . . . .	411
	<b>17.3.8.2</b>	Likely Radionuclides Involved . . .	411
	<b>17.3.8.3</b>	Radiological Considerations . . . .	411
	<b>17.3.8.4</b>	Important Nonradiological Considerations . . . . .	411
	<b>17.3.8.5</b>	Examples and Descriptions of Sources and Devices . . . . .	412
<b>17.3.9</b>		Medical . . . . .	412
	<b>17.3.9.1</b>	Examples of Contamination Incidents . . . . .	412
	<b>17.3.9.2</b>	Radiological Considerations . . . .	415
	<b>17.3.9.3</b>	Important Nonradiological Considerations . . . . .	415
	<b>17.3.9.4</b>	Examples and Descriptions of Sources and Devices . . . . .	415
<b>17.3.10</b>		Military . . . . .	416
	<b>17.3.10.1</b>	Examples of Contamination Incidents . . . . .	416
	<b>17.3.10.2</b>	Radiological Considerations . . . .	417
	<b>17.3.10.3</b>	Important Nonradiological Considerations . . . . .	419
	<b>17.3.10.4</b>	Examples and Descriptions of Sources and Devices . . . . .	419
<b>17.3.11</b>		Decontamination and Decommissioning . . .	419
	<b>17.3.11.1</b>	Examples of Contamination Incidents . . . . .	421
	<b>17.3.11.2</b>	Likely Radionuclides Involved . . .	421
	<b>17.3.11.3</b>	Radiological Considerations . . . .	421
	<b>17.3.11.4</b>	Important Nonradiological Considerations . . . . .	423
	<b>17.3.11.5</b>	Examples and Descriptions of Sources and Devices . . . . .	423
<b>17.3.12</b>		Research . . . . .	423
	<b>17.3.12.1</b>	Examples of Contamination Incidents . . . . .	423
	<b>17.3.12.2</b>	Radiological Considerations . . . .	424
	<b>17.3.12.3</b>	Important Nonradiological Considerations . . . . .	426

	<b>17.3.12.4</b>	Examples and Descriptions of Sources and Devices . . . . .	426
<b>17.3.13</b>		Field Activities . . . . .	426
	<b>17.3.13.1</b>	Examples of Contamination Incidents . . . . .	427
	<b>17.3.13.2</b>	Radiological Considerations . . . . .	428
	<b>17.3.13.3</b>	Important Nonradiological Considerations . . . . .	428
	<b>17.3.13.4</b>	Examples and Descriptions of Sources and Devices . . . . .	430
<b>17.3.14</b>		Spacecraft and Space-Based Applications . . . . .	430
	<b>17.3.14.1</b>	Examples of Contamination Incidents . . . . .	431
	<b>17.3.14.2</b>	Radiological Considerations . . . . .	431
	<b>17.3.14.3</b>	Important Nonradiological Considerations . . . . .	435
<b>17.4</b>		Conclusions and Summary . . . . .	435
<b>18. Roles and Responsibilities of Responders to Radionuclide Contamination Incidents . . . . . 437</b>			
<b>18.1</b>		Introduction . . . . .	437
<b>18.2</b>		Small-Scale versus Large-Scale Incidents . . . . .	438
	<b>18.2.1</b>	Small-Scale Incidents . . . . .	438
	<b>18.2.2</b>	Large-Scale Incidents . . . . .	438
<b>18.3</b>		Radionuclide Control Areas: Roles and Responsibilities . . . . .	439
	<b>18.3.1</b>	Inner Contaminated Area . . . . .	442
		<b>18.3.1.1</b> Law Enforcement . . . . .	443
		<b>18.3.1.2</b> Emergency Medical Responders . . . . .	443
		<b>18.3.1.3</b> Radiation Safety/Health Physics . . . . .	443
		<b>18.3.1.4</b> Public Health . . . . .	444
		<b>18.3.1.5</b> Other Emergency Responders . . . . .	444
	<b>18.3.2</b>	Outer Contaminated Area . . . . .	444
		<b>18.3.2.1</b> Law Enforcement . . . . .	445
		<b>18.3.2.2</b> Emergency Medical Responders . . . . .	445
		<b>18.3.2.3</b> Radiation Safety/Health Physics . . . . .	446
		<b>18.3.2.4</b> Public Health . . . . .	447
		<b>18.3.2.5</b> Other Emergency Responders . . . . .	448
	<b>18.3.3</b>	Secured Area . . . . .	448
		<b>18.3.3.1</b> Triage Area . . . . .	448
		<b>18.3.3.2</b> Medical-Response Base . . . . .	449
		<b>18.3.3.3</b> Decontamination Area . . . . .	449
	<b>18.3.4</b>	Secured Area Perimeter and Control Point . . . . .	450
		<b>18.3.4.1</b> Law Enforcement . . . . .	450
		<b>18.3.4.2</b> Emergency Medical Responders . . . . .	450

20.5	Cerium	522
20.6	Cesium	536
20.7	Cobalt	552
20.8	Curium	565
20.9	Europium	575
20.10	Hydrogen (Tritium)	585
20.11	Iodine	594
20.12	Iridium	605
20.13	Palladium	617
20.14	Phosphorus	623
20.15	Plutonium	632
20.16	Polonium	657
20.17	Radium	673
20.18	Rhenium	686
20.19	Ruthenium	692
20.20	Samarium	707
20.21	Strontium	715
20.22	Technetium	733
20.23	Thorium	739
20.24	Uranium	754
20.25	Yttrium	772
<b>21.</b>	<b>Dose-Assessment Methodologies</b>	<b>782</b>
21.1	Introduction	782
21.2	Collection of Data from the Individual	783
21.3	Interpretation of External Contamination Monitoring Data	785
21.4	Interpretation of Monitoring Data in Cases of Internal Contamination	786
21.4.1	Methods for Making Rapid Decisions Based on Monitoring Results	786
21.4.2	Use of Reference Values for Radionuclide Retention and Excretion	787
21.4.3	Considerations Regarding the Time of Intake	792
21.4.4	Intake Estimates from Multiple Bioassay Data	792
21.4.5	Particle Size/Chemical Composition	794
21.4.6	Intake Pathways	794
21.4.7	Model and Data Uncertainty	795
21.4.8	Modifications to the Reference Biokinetic Models	797
21.4.9	Direct Methods of Tritium Calculation	799
21.4.10	Interpretation of Air Monitoring Data	800
21.5	Initial Assessment of External Dose and Internal Radionuclide Deposition	801

<b>22. Research and Development</b>	802
<b>22.1</b> Decontamination Facilities for Removal of External Contamination	802
<b>22.2</b> Instrumentation and Modeling for Assessment of Internal Contamination	802
<b>22.3</b> Bioassay Facilities and Automation	804
<b>22.4</b> Biomarkers and Devices for Biodosimetry	805
<b>22.5</b> Software for Rapid Estimates of Organ Equivalent Dose and Effective Dose	805
<b>22.6</b> Decorporation Agents for Use Postexposure	806
<b>22.7</b> Medical Follow-Up of Exposed Populations	808
<b>22.8</b> Educational Programs	809
<b>Appendix A. Radiological Recordkeeping Following an Incident</b>	810
<b>A.1</b> Records for Exposed Persons	810
<b>A.2</b> Worker Records (Medical and Emergency Responders)	811
<b>A.3</b> Example Record Forms	812
<b>Appendix B. Training</b>	819
<b>B.1</b> Training Topics	820
<b>B.1.1</b> Law-Enforcement and Emergency-Response Personnel	820
<b>B.1.2</b> Emergency Medical Professionals	821
<b>B.1.3</b> Radiation Workers	822
<b>B.1.4</b> Radiation-Safety Personnel	822
<b>B.1.5</b> Public-Health Officials	823
<b>B.2</b> Drills and “Hands-On” Training	824
<b>B.3</b> Crisis and Risk Communications Training	824
<b>Appendix C. Emergency-Responders’ Guidance on Radiation Risks</b>	825
<b>C.1</b> Introduction	825
<b>C.2</b> Routes of Exposure	826
<b>C.2.1</b> Skin Contamination	826
<b>C.2.2</b> Inhalation and Ingestion	826
<b>C.3</b> Exposure to High Levels of Radiation	826
<b>C.3.1</b> Early Health Effects	826
<b>C.3.2</b> Late Health Effects	827
<b>C.4</b> Summary	828
<b>Appendix D. Communications with the Media and the Public via the Media</b>	829
<b>D.1</b> Introduction	829
<b>D.2</b> Audiences to Consider	830
<b>D.2.1</b> The Public	831

<b>D.2.2</b>	Medical Personnel . . . . .	832
<b>D.2.3</b>	Off-Duty Emergency Responders . . . . .	834
<b>D.2.4</b>	Those Outside the Affected Area . . . . .	835
<b>D.3</b>	Spokesperson . . . . .	835
<b>D.4</b>	Timeliness . . . . .	837
<b>D.5</b>	Correcting Information Already Provided . . . . .	838
<b>D.6</b>	Prescribed Statements to the Media . . . . .	839
<b>D.6.1</b>	Brief Example . . . . .	839
<b>D.6.2</b>	Other Information to Convey . . . . .	840
<b>Appendix E. Communicating with Patients and the Families of Patients Contaminated with Radionuclides . . . . .</b>		<b>842</b>
<b>Appendix F. Tables of Reference Values for Bioassay . . . . .</b>		<b>845</b>
<b>F.1</b>	Actinium . . . . .	846
<b>F.2</b>	Americium . . . . .	847
<b>F.3</b>	Californium . . . . .	849
<b>F.4</b>	Cerium . . . . .	851
<b>F.5</b>	Cesium . . . . .	853
<b>F.6</b>	Cobalt . . . . .	856
<b>F.7</b>	Curium . . . . .	859
<b>F.8</b>	Europium . . . . .	860
<b>F.9</b>	Hydrogen (Tritium) . . . . .	862
<b>F.10</b>	Iodine . . . . .	863
<b>F.11</b>	Iridium . . . . .	865
<b>F.12</b>	Palladium . . . . .	868
<b>F.13</b>	Phosphorus . . . . .	869
<b>F.14</b>	Plutonium . . . . .	871
<b>F.15</b>	Polonium . . . . .	876
<b>F.16</b>	Radium . . . . .	878
<b>F.17</b>	Rhenium . . . . .	879
<b>F.18</b>	Ruthenium . . . . .	880
<b>F.19</b>	Samarium . . . . .	884
<b>F.20</b>	Strontium . . . . .	886
<b>F.21</b>	Thorium . . . . .	889
<b>F.22</b>	Uranium . . . . .	891
<b>F.23</b>	Yttrium . . . . .	893
<b>Appendix G. Information Resources . . . . .</b>		<b>894</b>
<b>Appendix H. Additional Radionuclide Exposure Case Studies . . . . .</b>		<b>896</b>
<b>H.1</b>	Hanford Americium Accident (1976) . . . . .	896
<b>H.2</b>	Chernobyl Nuclear Reactor Accident (1986) . . . . .	902
<b>H.2.1</b>	Initial Response to the Accident . . . . .	902
<b>H.2.2</b>	Classification of Acute Radiation Sickness . . . . .	903

	<b>18.3.4.3</b>	Radiation Safety/Health Physics . . .	450
	<b>18.3.4.4</b>	Public Health . . . . .	451
	<b>18.3.4.5</b>	Other Emergency Responders . . .	451
<b>19. Instrumentation to Measure Radionuclide</b>			
	<b>Contamination</b>	. . . . .	452
<b>19.1</b>	Introduction	. . . . .	452
<b>19.2</b>	Direct ( <i>in vivo</i> ) Measurements of Body or Organ		
	Content	. . . . .	454
	<b>19.2.1</b>	Fixed-Facility Whole-Body Counters . . . . .	454
	<b>19.2.2</b>	Fixed-Facility Special Monitoring Systems . .	456
	<b>19.2.3</b>	Transportable Whole-Body Counters . . . . .	458
	<b>19.2.4</b>	Survey Meters for Large-Population Screening	
		Measurements . . . . .	458
	<b>19.2.5</b>	Special Considerations for Children and	
		Pregnant Women . . . . .	459
	<b>19.2.6</b>	Skin-Contamination Monitoring . . . . .	459
	<b>19.2.7</b>	Wound Monitoring . . . . .	461
		<b>19.2.7.1</b> Wound Monitors. . . . .	461
		<b>19.2.7.2</b> Survey Meters . . . . .	464
		<b>19.2.7.3</b> Sequential Measurements. . . . .	464
<b>19.3</b>	Indirect ( <i>in vitro</i> ) Measurements of Body or Organ		
	Content	. . . . .	465
	<b>19.3.1</b>	Urine Samples . . . . .	465
	<b>19.3.2</b>	Fecal Samples . . . . .	466
	<b>19.3.3</b>	Breath Samples . . . . .	467
	<b>19.3.4</b>	Blood Samples . . . . .	467
	<b>19.3.5</b>	Nose Blows and Nasal Swabs . . . . .	467
	<b>19.3.6</b>	Other Biological Samples . . . . .	468
	<b>19.3.7</b>	Analytical Methods and Techniques . . . . .	468
<b>19.4</b>	Contamination Survey Instrumentation and		
	Measurements . . . . .		469
	<b>19.4.1</b>	Surface-Contamination Measurements . . . .	473
		<b>19.4.1.1</b> Alpha-Emitter Monitoring . . . . .	476
		<b>19.4.1.2</b> Beta- and Gamma-Emitter	
		Monitoring . . . . .	476
		<b>19.4.1.3</b> Surface Monitoring with Swipes..	477
	<b>19.4.2</b>	Air Sampling . . . . .	477
<b>20. Dosimetry and Case Studies for Selected</b>			
	<b>Radionuclides</b>	. . . . .	482
<b>20.1</b>	Introduction	. . . . .	482
<b>20.2</b>	Actinium	. . . . .	485
<b>20.3</b>	Americium	. . . . .	493
<b>20.4</b>	Californium	. . . . .	509

<b>H.2.3</b>	Early Clinical Response and Treatment . . . .	905
<b>H.2.4</b>	Bone-Marrow Transplantation . . . . .	907
<b>H.2.5</b>	Evacuated Population . . . . .	907
<b>H.2.6</b>	Late Effects of Radiation . . . . .	908
<b>H.3</b>	Goiânia Incident (1987) . . . . .	908
<b>H.4</b>	National Institutes of Health and Massachusetts Institute of Technology <sup>32</sup> P Incidents (1995) . . . . .	915
<b>H.4.1</b>	NIH <sup>32</sup> P Contamination . . . . .	916
<b>H.4.2</b>	MIT <sup>32</sup> P Incident . . . . .	916
<b>Appendix I. Validation and Verification of Computational Approach . . . . .</b>		<b>918</b>
<b>Appendix J. Pregnancy Categories for Drug Use . . . . .</b>		<b>920</b>
<b>Glossary . . . . .</b>		<b>921</b>
<b>Abbreviations and Acronyms . . . . .</b>		<b>943</b>
<b>References . . . . .</b>		<b>946</b>
<b>The NCRP . . . . .</b>		<b>993</b>
<b>NCRP Publications . . . . .</b>		<b>1002</b>
<b>Index . . . . .</b>		<b>1013</b>